| Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, changing, or stopping any medication. |
| Key Takeaways |
| • Dulaglutide (brand name: Trulicity) is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes management and cardiovascular risk reduction. |
| • The REWIND trial found a 12% reduction in major cardiovascular events and a 15% reduction in composite renal outcomes over 5.4 years. |
| • Common side effects include nausea, diarrhea, and vomiting, especially in the first weeks. Serious side effects are less common but require prompt attention. |
If your doctor has prescribed dulaglutide, or is considering it as part of your diabetes care.<\/p>
This guide covers exactly what it is, how it works, what the clinical evidence shows, and what you need to know before and during treatment.
1. What Exactly Is Dulaglutide (Trulicity)?
Dulaglutide is the generic namefor the prescription injectable medication marketed under the brand name Trulicity, manufactured by Eli Lilly and Company.
It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking a naturally occurring gut hormone.
A 2022 regulatory review confirmed its use in children and adolescents 10 years of age and older with type 2 diabetes.
It is not insulin. Dulaglutide does not introduce insulin into the body. Instead, it stimulates the pancreas to produce its own insulin when blood sugar rises, while also reducing signals that push blood sugar higher.
| Quick Facts | Details |
|---|---|
| Generic name | Dulaglutide |
| Brand name | Trulicity |
| Manufacturer | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist (incretin mimetic) |
| FDA approval (Type 2 Diabetes) | September 2014 |
| FDA approval (Cardiovascular Risk Reduction) | 2020 |
| Dosing frequency | Once weekly (subcutaneous injection) |
| Available doses | 0.75 mg, 1.5 mg, 3 mg, 4.5 mg per 0.5 mL single-dose pen |
| Available in India | Yes, as Trulicity (prescription required) |
2. How Does Dulaglutide Work Inside the Body?
To understand how dulaglutide works, it helps to start with GLP-1 (glucagon-like peptide-1): a hormone your intestines release naturally after a meal.
It signals the pancreas to release insulin, tells the liver to slow glucose production, and sends fullness signals to the brain.
In people with type 2 diabetes, this system does not function efficiently enough. Dulaglutide steps in by mimicking GLP-1 at the receptor level, amplifying these signals for a full seven days with each single dose.<\/p>
The Three Core Mechanisms
1. Glucose-dependent insulin release: Dulaglutide activates GLP-1 receptors on pancreatic beta cells, triggering insulin secretion. This process only occurs when blood glucose is already elevated, which is why the risk of hypoglycemia is significantly lower compared to traditional insulin or sulfonylurea therapy when dulaglutide is used on its own.
2. Glucagon suppression: Dulaglutide reduces glucagon, a hormone that signals the liver to release stored glucose into the bloodstream. Lower glucagon levels mean lower fasting and post-meal blood sugar.
3. Slowed gastric emptying: Food moves more slowly through the stomach, flattening sharp blood sugar spikes after meals. This also contributes to a feeling of fullness, which may reduce overall calorie intake in many patients.
What Is Dulaglutide Actually Made Of?
Dulaglutide is a biosynthetic fusion protein, engineered from two identical GLP-1 analogue chains, each linked to a modified human immunoglobulin G4 (IgG4) antibody fragment via a small peptide connector.
According to the FDA prescribing information, it shares 90% amino acid sequence homology with endogenous human GLP-1. This molecular design extends its half-life to approximately 5 days, making once-weekly dosing both practical and effective.
The medication is produced using mammalian cell cultures through recombinant DNA technology.
3. What Is Dulaglutide Approved to Treat?
Dulaglutide has two distinct FDA-approved indications. Understanding both matters for patients and caregivers.
Primary Indication: Type 2 Diabetes Management
Dulaglutide is approved as an adjunct to diet and exercise to improve glycemic control in adults and children aged 10 and older with type 2 diabetes mellitus.
It may be used alone (monotherapy) or in combination with other anti-diabetes medications including metformin, sulfonylureas, and insulin.
It is not approved for type 1 diabetes. It should not be used for diabetic ketoacidosis.
Second Indication: Cardiovascular Risk Reduction
In 2020, the FDA approved dulaglutide to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
This made dulaglutide the first GLP-1 receptor agonist with an approved indication for both primary and secondary cardiovascular prevention in this population.
This approval was built on the landmark REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial, published in The Lancet in 2019, and is discussed in detail in Section 4.
Regarding weight: dulaglutide is not FDA-approved as a weight loss medication. Modest weight reduction is a recognized secondary effect in many patients using it for diabetes, which is discussed further in Section 8.
4. What Does the Clinical Evidence Show?
Dulaglutide is among the most thoroughly studied medications in the GLP-1 class. Here is a focused summary of the major trials.
Blood Sugar Control: The AWARD Trial Program
The AWARD (Assessment of Weekly Administration of LY2189265 [dulaglutide] in Diabetes) trial program comprised multiple phase 3 studies across more than 3,342 patients
Across these trials, dulaglutide consistently reduced HbA1c from baseline in a dose-dependent manner.<\/p>
| Dulaglutide Dose | Mean HbA1c Reduction | Mean Weight Change at 36 Weeks |
|---|---|---|
| 0.75 mg week | Approx. 1.0% | Approx. -1.5 to -2.3 kg |
| 1.5 mg week | Approx. 1.1% to 1.5% | Approx. -2.3 to -3.0 kg |
| 3.0 mg week | Approx. 1.5% to 2.5%*< | Approx. -4.0 kg* |
| 4.5 mg week | Approx. 1.7% to 3.2%* | Approx. -4.7 kg* |
Heart Health: The REWIND Trial
The REWIND trial enrolled 9,901 participants across 371 sites in 24 countries, followed over a median of 5.4 years
Critically, approximately two-thirds of participants had no prior cardiovascular event and were enrolled based on cardiovascular risk factors alone, making this one of the broadest cardiovascular outcome trials conducted for a GLP-1 medication.
Key findings, published in The Lancet (2019)
- 12% relative reduction in MACE (cardiovascular death, non-fatal heart attack, or non-fatal stroke)
- 24% reduction in non-fatal stroke specifically
- Benefits observed in patients with and without prior established cardiovascular disease
Kidney Health: REWIND Renal Analysis
An exploratory analysis of REWIND, published in The Lancet (2019), found that long-term dulaglutide use was associated with a 15% relative reduction in composite renal outcomes (HR 0.85, 95% CI 0.77-0.93, p=0.0004).
The strongest effect was a 23% reduction in new macroalbuminuria (HR 0.77, p<0.0001), an early marker of kidney damage in diabetes.
These findings support dulaglutide’s potential kidney-protective effects in people managing type 2 diabetes with cardiovascular risk.
5. Dulaglutide Dosage: How Much and How to Take It
Dulaglutide comes as a pre-filled, single-dose pen containing 0.5 mL of clear, colorless solution. It is injected once a week under the skin (subcutaneously). It is not injected into a muscle or vein.
The Standard Dose Escalation Schedule
Your doctor will typically start at the lowest dose and increase gradually. This step-up approach is specifically designed to reduce GI side effects while your body adapts.
| Stage | Dose | Purpose |
|---|---|---|
| Weeks 1 to 4 | 0.75 mg once weekly | Starting dose: establish GI tolerance |
| Week 5 onward | 1.5 mg once weekly | Standard maintenance dose for most patients |
| If additional control needed (minimum 4-week intervals) | 3.0 mg once weekly | Dose escalation step |
| Maximum approved dose | 4.5 mg once weekly | Approved since 2020 for patients requiring further glycemic control |
Per the FDA prescribing information, the maximum approved dose is 4.5 mg once weekly. Dose changes should occur at intervals of at least 4 weeks.
How to Inject Dulaglutide Correctly
- Inject into the abdomen, thigh, or upper arm subcutaneously (under the skin).
- Rotate the injection site with each dose to reduce the chance of skin irritation.
- The injection may be taken with or without food, at any time of day.
- Aim to use it on the same day each week for consistency.
- Allow the pen to reach room temperature before injecting.
- Do not mix dulaglutide with insulin in the same syringe. They may be used in the same body area, but not at adjacent spots.
- Never share your pen with another person.
- Store in the refrigerator (2 degrees C to 8 degrees C). The pen may be kept at room temperature for up to 14 days if temporary refrigeration is unavailable. Never freeze it.
If you miss a dose, use it as soon as you remember. If your next scheduled dose is 3 or fewer days away, skip the missed dose and resume your regular schedule. Never take a double dose.
Always follow the specific instructions provided by your doctor or pharmacist. The above is general guidance only.
6. Dulaglutide Side Effects: Common and Serious
Like all prescription medications, dulaglutide may cause side effects. The majority are gastrointestinal and tend to be mild to moderate, particularly during the first weeks.
Common Side Effects (Affecting More Than 1 in 10 People)
Based on clinical trial data cited in the FDA label
| Side Effect | Reported Frequency | When It Typically Occurs |
|---|---|---|
| Nausea | Up to 21.1% | First 2 to 3 days after initial dose or after a dose increase; usually eases within 2 weeks |
| Diarrhea | Up to 13.7% | Early weeks of treatment |
| Vomiting | Up to 11.5% | Early weeks; more frequent at higher doses |
| Abdominal pain | 1% to 10% | Throughout treatment; usually mild |
| Decreased appetite | 1% to 10% | Common; contributes to modest weight reduction |
| Indigestion GERD | 1% to 10% | Ongoing; related to slower gastric emptying |
| Fatigue | 1% to 10% | Primarily in early weeks |
GI side effects are dose-dependent and tend to ease as the body adjusts. Eating smaller, lower-fat meals, staying well hydrated, and avoiding lying down after eating may help manage these effects in the early weeks.
Serious Side Effects That Require Immediate Attention
While uncommon, the following require prompt medical evaluation:
- Pancreatitis: Sudden, severe abdominal or back pain, sometimes with nausea or vomiting. During clinical trials, 5 confirmed cases of pancreatitis were reported in dulaglutide-exposed patients versus 1 in the comparator group. Discontinue the medication and seek medical care if pancreatitis is suspected.
- Thyroid tumor risk (boxed warning): Dulaglutide caused thyroid C-cell tumors in rodent studies. Human relevance is not established, but contact your doctor if you notice a lump in the neck, hoarseness, difficulty swallowing, or shortness of breath. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Acute kidney injury: Primarily reported in patients who became severely dehydrated from vomiting or diarrhea. Drink adequate fluids, especially during the first weeks of treatment.
- Hypoglycemia: Dulaglutide alone carries a low hypoglycemia risk. That risk increases when combined with insulin or sulfonylureas. Symptoms include shakiness, sweating, confusion, and rapid heartbeat.
- Gallbladder disease: GLP-1 receptor agonists as a class may increase the risk of gallbladder events. Report persistent upper-right abdominal pain, fever, or jaundice to your doctor.
- Serious allergic reactions: Rare but possible. Seek emergency care immediately if you develop hives, facial or throat swelling, or difficulty breathing.
| This is not an exhaustive list. Please refer to the full prescribing information or discuss all potential side effects with your doctor or pharmacist. |
7. Who Should and Should Not Take Dulaglutide?
Not every person with type 2 diabetes is a suitable candidate. Your doctor will evaluate your full medical history before prescribing.
Who May Benefit Most
- Adults and children aged 10 and older with type 2 diabetes who need better blood sugar control alongside diet and exercise.
- Patients with type 2 diabetes who also have established cardiovascular disease or multiple cardiovascular risk factors.
- Patients with chronic kidney disease: dulaglutide does not require renal dose adjustments and may offer kidney-protective benefits based on REWIND renal data.
- Those who prefer a convenient once-weekly injection over daily injections or additional oral tablets.
Who Should Not Take Dulaglutide
| Contraindication or Caution | Reason |
|---|---|
| Personal or family history of medullary thyroid carcinoma (MTC) | Boxed warning: potential thyroid C-cell tumor risk |
| Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) | Boxed warning |
| Serious hypersensitivity to dulaglutide or its components | Risk of anaphylaxis or serious allergic reaction |
| Type 1 diabetes | Not approved; does not address the underlying mechanism of type 1 diabetes |
| Diabetic ketoacidosis (DKA) | Not indicated for DKA treatment |
| History of pancreatitis | Use with caution; discontinue immediately if pancreatitis occurs |
| Severe gastroparesis | Dulaglutide further slows gastric emptying |
| Pregnancy and breastfeeding | Safety not established; discuss with your doctor |
Talk with your doctor about all medications, supplements, and herbal products you take. Dulaglutide may affect the absorption of other oral medications due to its effect on gastric emptying.
8. Dulaglutide and Weight Loss: What to Realistically Expect
This is among the most frequently asked questions about dulaglutide, particularly given the current interest in GLP-1 medications for weight management.
The direct answer: dulaglutide is not approved as a weight loss medication. However, it may produce modest weight reduction as a secondary effect due to slowed gastric emptying and reduced appetite.
In the AWARD-11 trial, weight reductions at 36 weeks were dose-dependent: patients on 1.5 mg lost approximately 3.1 kg, those on 3.0 mg lost approximately 4.0 kg, and those on 4.5 mg lost approximately 4.7 kg on average.
Overall, most published data suggest weight reductions in the range of 3 to 5% of body weight in clinical trial settings.
This is considerably more modest than what is typically observed with higher-dose semaglutide formulations (Ozempic at therapeutic doses, or Wegovy), which can produce weight reductions of 10 to 15%+ in clinical trials.
For patients whose primary goal is significant weight loss, this distinction is clinically important, and a doctor may recommend a dedicated GLP-1 weight loss program or alternative medication approved specifically for that purpose.
For patients using dulaglutide to manage type 2 diabetes and associated metabolic risk, even modest weight reductions can meaningfully improve blood sugar control, blood pressure, and cardiovascular outcomes. Any changes in weight should be discussed within the context of your overall health goals.<\/p>
The Bottom Line
Dulaglutide (Trulicity) is a well-studied, once-weekly injectable GLP-1 receptor agonist with strong clinical evidence behind it. In the AWARD trial program, it reduced HbA1c by up to 1.9%. In the landmark REWIND trial, it lowered the risk of major cardiac events by 12% and reduced composite renal outcomes by 15% over more than 5 years of follow-up.
Most side effects are GI-related and ease within the first few weeks. Serious side effects are uncommon but recognizable, and prompt medical attention makes all the difference.
Dulaglutide is a prescription-only medication, and the right dose and treatment approach depend entirely on your individual health profile. Always work with your endocrinologist, diabetologist, or primary care physician to determine whether it is appropriate for you.
Frequently Asked Questions About Dulaglutide
Is dulaglutide the same as insulin?
No. Dulaglutide is not insulin. It is a GLP-1 receptor agonist that works by stimulating the body’s own pancreas to release insulin in response to elevated blood glucose.
Unlike insulin, it does not directly introduce insulin into the body, and it carries a substantially lower risk of hypoglycemia when used on its own.
Some patients may use both dulaglutide and insulin simultaneously, as prescribed by their doctor.
What is dulaglutide made of, and how is it produced?
Dulaglutide is a biosynthetic fusion protein. It consists of two identical GLP-1 analogue chains, each linked to a modified human IgG4 antibody fragment.
According to the FDA prescribing information, it has 90% amino acid sequence homology to endogenous human GLP-1 and is produced using mammalian cell cultures through recombinant DNA technology. <\/p>
Each 0.5 mL pen contains dulaglutide along with citric acid, mannitol, polysorbate 80, and trisodium citrate dihydrate in water for injection.
Can dulaglutide be used for weight loss in India?
Dulaglutide is not approved as a weight loss medication in India or globally. Modest weight reduction, typically 3 to 5% of body weight, may occur as a secondary effect in patients using it for type 2 diabetes management.
If weight management is your primary treatment goal, discuss dedicated options with your doctor — including those in the MetaGo weight loss program — as other GLP-1 medications have stronger evidence and regulatory approval specifically for weight management.
What is the difference between dulaglutide (Trulicity) and semaglutide (Ozempic)?
Both are GLP-1 receptor agonists, but they differ in molecular structure, available doses, and clinical outcomes. Semaglutide at higher approved doses tends to produce greater HbA1c reductions and significantly more weight loss.
Dulaglutide has particularly robust cardiovascular outcome data from the REWIND trial, including benefits in primary cardiovascular prevention.
The right choice depends on your individual health profile, coexisting conditions, and treatment goals. For a detailed head-to-head comparison, see our semaglutide vs dulaglutide guide. Your doctor is best placed to advise which is more appropriate for you.
How long does dulaglutide take to show results?
Most patients see meaningful improvements in fasting blood glucose within the first 2 to 4 weeks. HbA1c reductions become measurable at the first routine follow-up, typically after 12 weeks
Full benefits at a given dose generally stabilize over 3 to 6 months. GI side effects, if present, usually improve considerably after the first 2 weeks.
